Guidelines for Cardiovascular Disease Prevention and Management in COVID-19

Overview

This consensus document from leading European cardiovascular associations outlines comprehensive strategies to prevent and manage cardiovascular complications associated with COVID-19. It emphasizes the importance of early cardiovascular risk assessment, targeted rehabilitation, and personalized therapeutic approaches across acute infection, Long COVID, reinfection, and post-vaccination phases.

Background

COVID-19, caused by SARS-CoV-2, has led to significant global morbidity and mortality, with cardiovascular complications being a major contributor to adverse outcomes. These complications can arise during the acute infection phase and persist as part of Long COVID, affecting a substantial proportion of patients. Cardiovascular manifestations include myocarditis, thrombotic events, arrhythmias, and heart failure, which may be exacerbated by treatments like corticosteroids. Given the complexity and evolving nature of COVID-19’s cardiovascular impact, tailored prevention and management strategies are urgently needed.

Data Highlights

Over 10 million deaths and nearly 1 billion COVID-19 cases have been reported worldwide. More than 20% of Long COVID patients experience cardiac symptoms, suggesting that 2–5% of all infected individuals may develop Cardiac Long COVID. Cardiovascular risk factors such as inflammation, endothelial dysfunction, and thrombosis are significantly elevated following acute infection, increasing the risk of myocarditis, myocardial infarction, heart failure, and thromboembolism.

Key Findings

• COVID-19 can trigger acute and long-term cardiovascular complications including myocarditis, pericarditis, thrombotic events, arrhythmias, and heart failure.
• Long COVID cardiovascular symptoms affect over 20% of patients with persistent symptoms, complicating diagnosis and management.
• Pre-existing cardiovascular disease and risk factors exacerbate COVID-19 severity and outcomes.
• Early cardiovascular risk assessment and prevention post-infection are critical, especially in patients with elevated cardiac biomarkers.
• Targeted cardiovascular rehabilitation and lifestyle modifications are recommended to improve recovery and reduce long-term sequelae.
• Personalized therapeutic approaches are essential due to the heterogeneity of cardiovascular manifestations and patient populations.

Clinical Implications

Clinicians should proactively assess and manage cardiovascular risk in all patients following COVID-19 infection, with particular attention to those exhibiting elevated cardiac injury markers. Implementation of individualized rehabilitation programs and lifestyle interventions can mitigate long-term cardiovascular complications. Awareness of Cardiac Long COVID is essential to avoid misdiagnosis and inappropriate treatments.

Conclusion

This consensus provides a comprehensive framework for cardiovascular prevention and management throughout the COVID-19 disease continuum, emphasizing early intervention and personalized care to improve patient outcomes. Ongoing research is needed to refine strategies and address knowledge gaps in this evolving field.

References

1. European Society of Cardiology Consensus Statement 2024 -- Guidelines for the Prevention and Management of Cardiovascular Disease in the Context of COVID-19